Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Usrc Kidney Research LLC

Neither a doctor nor a teaching hospital

Research payments

$11,648,840

111 payments

Through program year 2025, Usrc Kidney Research LLC is reported as receiving $11,648,840 in research payments, across 111 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $4,017,470 14
2024 Research $2,175,558 13
2023 Research $1,584,202 31
2022 Research $3,830,930 48
2021 Research $1,679 1
2020 Research $39,000 4

Breakdown

Who paid Research payments · program years 2020–2025
  1. Akebia Therapeutics Inc $9,681,490 83 payments
  2. Bayer HealthCare Pharmaceuticals Inc. $1,064,732 8 payments
  3. GlaxoSmithKline, LLC. $850,374 9 payments
  4. AstraZeneca Pharmaceuticals LP $39,000 4 payments
  5. Grifols, S.A. $13,244 7 payments
Studies the money was for Research payments · program years 2020–2025
  1. Safety of Three Times Weekly Oral Vadadustat for the Treatment of Anemia in Hemodialysis Subjects: Vafseo Outcomes In-Center Experience $4,504,046 10 payments
  2. Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Determine the Effect of Ferric Citrate on Time to a Composite Endpoint of Initiation of Maintenance Dialysis or All-cause Mortality vs Placebo in Adults With Advanced CKD $2,994,602 36 payments
  3. A Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Impact of Auryxia (Ferric Citrate) on Erythropoiesis-Stimulating Agent (ESA) Use, Intravenous (IV) Iron Use, Phosphate Control, and Anemia Control in Adult Participants on In-Center Hemodialysis or Home Dialysis $1,773,465 35 payments
  4. GEMINI - 2 -: Quality Improvement Project for management of CKD-T2D Patients in a large Nephrology practice $1,064,732 8 payments
  5. Clinical Effectiveness of Transitioning From Mircera to Daprodustat $850,374 9 payments
  6. Vafseo Outcomes In-Center Experience (VOICE) $409,376 2 payments
  7. A Phase 2a Randomized Double blind Placebo-controlled Study to Evaluate the Efficacy and Safety of MEDI3506 in Subjects with Diabetic Kidney Disease $39,000 4 payments
  8. An Open Label Phase 1 Study to Compare the Safety and Tolerability of the AKST1210 Column at Different Blood-Flow Rates in Patients With End-Stage Renal Disease Undergoing Hemodialysis $13,244 7 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record